This company listing is no longer active
Atreca Management
Management criteria checks 3/4
Atreca's CEO is John Orwin, appointed in Apr 2018, has a tenure of 6.17 years. total yearly compensation is $927.03K, comprised of 64.8% salary and 35.2% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth €3.37K. The average tenure of the management team and the board of directors is 5 years and 5.5 years respectively.
Key information
John Orwin
Chief executive officer
US$927.0k
Total compensation
| CEO salary percentage | 64.8% |
| CEO tenure | 6.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 5yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$98m |
| Jun 30 2023 | n/a | n/a | -US$85m |
| Mar 31 2023 | n/a | n/a | -US$93m |
| Dec 31 2022 | US$927k | US$601k | -US$97m |
| Sep 30 2022 | n/a | n/a | -US$105m |
| Jun 30 2022 | n/a | n/a | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$4m | US$583k | -US$109m |
| Sep 30 2021 | n/a | n/a | -US$103m |
| Jun 30 2021 | n/a | n/a | -US$98m |
| Mar 31 2021 | n/a | n/a | -US$92m |
| Dec 31 2020 | US$5m | US$567k | -US$86m |
| Sep 30 2020 | n/a | n/a | -US$83m |
| Jun 30 2020 | n/a | n/a | -US$76m |
| Mar 31 2020 | n/a | n/a | -US$74m |
| Dec 31 2019 | US$845k | US$507k | -US$67m |
| Sep 30 2019 | n/a | n/a | -US$59m |
| Jun 30 2019 | n/a | n/a | -US$53m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$5m | US$319k | -US$38m |
Compensation vs Market: John's total compensation ($USD927.03K) is above average for companies of similar size in the German market ($USD434.04K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Orwin (59 yo)
6.2yrs
Tenure
US$927,033
Compensation
Mr. John A. Orwin, M.B.A. serves as Chairman of the Board for Nested Therapeutics since February 2024. He serves as Independent Chairman of the Board of AnaptysBio, Inc. since September 15, 2023. He has be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.2yrs | US$927.03k | 0.20% € 3.4k | |
| Founder & Director | no data | US$665.50k | 0.81% € 14.0k | |
| Principal Accounting Officer | less than a year | no data | no data | |
| General Counsel & Corporate Secretary | 5yrs | no data | 0.073% € 1.3k | |
| Vice President of Finance | no data | no data | 0.067% € 1.2k |
5.0yrs
Average Tenure
59.5yo
Average Age
Experienced Management: 0C1's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.2yrs | US$927.03k | 0.20% € 3.4k | |
| Founder & Director | 14.4yrs | US$665.50k | 0.81% € 14.0k | |
| Independent Chairman of the Board | 10.5yrs | US$97.77k | 0.13% € 2.2k | |
| Chairman of External Scientific Advisory Board & Technical Advisor | 4.8yrs | US$150.00k | no data | |
| Independent Director | 4.1yrs | US$64.27k | 0% € 0 | |
| Director | 13.4yrs | US$312.77k | 0.93% € 16.0k | |
| Independent Director | 8.1yrs | US$70.77k | 0% € 0 | |
| Independent Director | 2.9yrs | US$60.27k | 0% € 0 | |
| Board Observer | no data | no data | no data | |
| Board Observer | no data | no data | no data | |
| Independent Director | 4.8yrs | US$62.77k | 0% € 0 | |
| Independent Director | 2.9yrs | US$57.77k | 0% € 0 |
5.5yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 0C1's board of directors are considered experienced (5.5 years average tenure).